Longevity & AgingResearch PaperOpen Access

New Anti-CD38 Antibody Boosts NAD+ and Curbs Deadly Immune Overreaction

TNB-738 blocks CD38's NAD+-degrading activity on human immune cells, reducing inflammation and improving survival in a preclinical GvHD model.

Tuesday, October 6, 2026 1 view
Published in Front Immunol
Glowing molecular antibody latching onto a CD38 receptor on a human T cell, with NAD+ molecules accumulating inside the cell

Summary

Researchers developed TNB-738, a fully human antibody that inhibits the enzyme CD38 on immune cells without depleting them. CD38 normally breaks down NAD+, a molecule critical for cellular energy, DNA repair, and immune regulation. By blocking this enzymatic activity in a mouse model of xenogeneic graft-versus-host disease (xeno-GvHD), TNB-738 raised intracellular NAD+ levels, expanded regulatory T cells, reduced inflammatory gene expression, and significantly improved survival. Unlike existing CD38-targeting drugs such as daratumumab, TNB-738 does not kill immune cells, preserving the anti-tumor immune response. These findings position CD38 enzyme inhibition as a promising new therapeutic strategy for GvHD and potentially other inflammatory and aging-related diseases.

Detailed Summary

NAD+ is indispensable for cellular metabolism, DNA repair, epigenetic regulation, and mitochondrial function. CD38, a multifunctional ectoenzyme highly expressed on immune cells, is the primary consumer of NAD+ in tissues. Its expression rises sharply with age and during inflammation, driving NAD+ depletion and fueling a vicious cycle of metabolic dysfunction and chronic immune activation. Inhibiting CD38's enzymatic activity—without destroying the cells that express it—has emerged as an attractive strategy to restore NAD+ homeostasis in aging, fibrosis, and inflammatory disease.

The team engineered TNB-738, a fully human, effector-silenced IgG4 antibody that potently blocks human CD38 NADase and NMNase activities. In vitro characterization confirmed that TNB-738 raises intracellular NAD+ in human immune cells in a dose-dependent manner, activates Sirtuin-1 (a key NAD+-dependent deacetylase), and does not trigger antibody-dependent cytotoxicity, complement-dependent cytotoxicity, or receptor internalization—distinguishing it mechanistically from daratumumab and isatuximab.

To test in-vivo efficacy, the researchers used an established xenogeneic GvHD model: human PBMCs were infused into immunodeficient NSG mice, where alloreactive human T cells expand and attack host tissues, culminating in lethal multi-organ inflammation. TNB-738 was administered for 18 days post-engraftment. Treated mice showed markedly lower clinical disease scores, prolonged overall survival, and reduced total expansion of engrafted human CD45+ cells compared to vehicle controls. Critically, Treg populations expanded significantly in TNB-738-treated animals, suggesting a shift toward immune tolerance. Ex vivo stimulation confirmed that human T cells recovered from spleen and bone marrow of treated mice remained functionally competent, and GvT activity against tumor targets was preserved.

Mechanistic readouts reinforced the NAD+ axis as the operative pathway. Liver and spleen tissue from treated mice contained elevated NAD+ concentrations. RNA sequencing of purified human CD45+ blood cells at day 11 revealed upregulated mitochondrial homeostasis genes and downregulated T cell activation signatures. Untargeted metabolomics of liver tissue showed reduced markers of oxidative stress, inflammation, and tissue turnover. Because TNB-738 is human-specific and antibody Ab68 (targeting murine CD38) had no effect on disease, the authors concluded that the metabolic improvements in surrounding murine tissues were secondary to reduced NAD+ consumption by the infiltrating human immune cells—demonstrating a paracrine bystander benefit.

These results establish proof-of-concept that selective inhibition of CD38 enzymatic activity, decoupled from immune cell depletion, can mitigate pathological inflammation while preserving immune competence. The approach is conceptually distinct from existing CD38 antibodies and may offer a safer therapeutic window for GvHD and potentially for other NAD+-depleting inflammatory and age-related conditions. Caveats include the xenogeneic nature of the model, the short treatment window studied, and the need for primate or human clinical data to confirm translation.

Key Findings

  • TNB-738 raised intracellular NAD+ in human immune cells dose-dependently without depleting CD38+ cells.
  • Treated xeno-GvHD mice had significantly lower disease scores and prolonged survival versus vehicle controls.
  • Treg populations expanded significantly in TNB-738-treated mice, indicating a tolerogenic immune shift.
  • Liver metabolomics showed reduced oxidative stress and inflammation markers in treated animals.
  • Anti-tumor (GvT) responses of engrafted human T cells were fully preserved under TNB-738 treatment.

Methodology

Human PBMCs were infused into immunodeficient NSG mice to generate a xenogeneic GvHD model; TNB-738 was administered for 18 days post-engraftment. Outcomes included clinical scoring, survival, flow cytometry of immune subsets, NAD+ quantification in tissues, bulk RNA sequencing of purified human CD45+ cells, and untargeted metabolomics of liver tissue.

Study Limitations

The xenogeneic NSG mouse model does not fully replicate human allo-HSCT immunology, limiting direct translational conclusions. The study used a short 18-day treatment window and did not evaluate chronic dosing, pharmacokinetics, or safety in non-human primates or humans.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: